JP2016538288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538288A5 JP2016538288A5 JP2016530882A JP2016530882A JP2016538288A5 JP 2016538288 A5 JP2016538288 A5 JP 2016538288A5 JP 2016530882 A JP2016530882 A JP 2016530882A JP 2016530882 A JP2016530882 A JP 2016530882A JP 2016538288 A5 JP2016538288 A5 JP 2016538288A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- pharmaceutical composition
- ohepa
- hetre
- hode
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000003839 salts Chemical group 0.000 claims 9
- BFWYTORDSFIVKP-QUFQRZHPSA-N (5E,8Z,11Z,13Z,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid Chemical compound CCCCC[C@H](OO)\C=C/C=C\C\C=C/C\C=C\CCCC(O)=O BFWYTORDSFIVKP-QUFQRZHPSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- JDSRHVWSAMTSSN-BSZOFBHHSA-N (9Z,11E)-13-hydroperoxyoctadeca-9,11-dienoic acid Chemical compound CCCCCC(OO)\C=C\C=C/CCCCCCCC(O)=O JDSRHVWSAMTSSN-BSZOFBHHSA-N 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- YIYBQIKDCADOSF-ARJAWSKDSA-N cis-pent-2-enoic acid Chemical compound CC\C=C/C(O)=O YIYBQIKDCADOSF-ARJAWSKDSA-N 0.000 claims 2
- 150000004885 piperazines Chemical class 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 206010000496 Acne Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (10)
- 塩形態の13-ヒドロペルオキシオクタデカ-9Z,11E-ジエン酸（13-HODE）、15-ヒドロペルオキシ-エイコサ-8(Z),11(Z),13(E)-トリエン酸（15-HETrE）、15-ヒドロペルオキシ-エイコサ-5(Z),8(Z),11(Z),13(E),17(Z)-ペンタエン酸（15-OHEPA）、又は15-ヒドロペルオキシ-5,8,11,13-エイコサテトラエン酸（15-HETE）であって、リジン塩、ナトリウム塩、オルニチン塩、ピペラジン塩、メグルミン塩、又はそれらの組み合わせである、前記塩。
- 薬学的に許容される塩である、請求項１記載の塩。
- 塩形態の13-ヒドロペルオキシオクタデカ-9Z,11E-ジエン酸（13-HODE）、15-ヒドロペルオキシ-エイコサ-8(Z),11(Z),13(E)-トリエン酸（15-HETrE）、15-ヒドロペルオキシ-エイコサ-5(Z),8(Z),11(Z),13(E),17(Z)-ペンタエン酸（15-OHEPA）、又は15-ヒドロペルオキシ-5,8,11,13-エイコサテトラエン酸（15-HETE）を含む薬学的組成物であって、該塩が、リジン塩、ナトリウム塩、オルニチン塩、ピペラジン塩、メグルミン塩、又はそれらの組み合わせである、前記薬学的組成物。
- 賦形剤をさらに含む、請求項３記載の薬学的組成物。
- 少なくとも約4週間の保管後、前記薬学的組成物が、前記塩形態の13-HODE、15-HETrE、15-OHEPA、又は15-HETEの初期量の少なくとも約98％、少なくとも約99％、又は約100％を含む、請求項３又は４記載の薬学的組成物。
- 少なくとも約10週間の保管後、前記薬学的組成物が、前記塩形態の13-HODE、15-HETrE、15-OHEPA、又は15-HETEの初期量の少なくとも約90％、少なくとも約91％、少なくとも約92％、少なくとも約93％、少なくとも約94％、少なくとも約95％、少なくとも約96％、少なくとも約97％、少なくとも約98％、少なくとも約99％、又は約100％を含む、請求項３〜５のいずれか一項記載の薬学的組成物。
- 前記薬学的組成物が、前記塩形態の13-HODE、15-HETrE、15-OHEPA、又は15-HETEの治療有効量を含む、請求項３〜６のいずれか一項記載の薬学的組成物。
- 前記塩形態の13-HODE、15-HETrE、15-OHEPA、又は15-HETEの治療有効量が、約0.1重量％〜約20重量％である、請求項７記載の薬学的組成物。
- 前記薬学的組成物が、局所投与に好適な形態である、請求項３〜８のいずれか一項記載の薬学的組成物。
- それを必要とする対象において、ざ瘡、紅斑、感染、脂肪肝、神経障害、又は皮膚炎症若しくは障害を治療するための医薬の製造における、請求項３〜９のいずれか一項記載の薬学的組成物の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904600P | 2013-11-15 | 2013-11-15 | |
| US61/904,600 | 2013-11-15 | ||
| PCT/IB2014/003027 WO2015071766A1 (en) | 2013-11-15 | 2014-11-17 | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019212877A Division JP6818851B2 (ja) | 2013-11-15 | 2019-11-26 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538288A JP2016538288A (ja) | 2016-12-08 |
| JP2016538288A5 true JP2016538288A5 (ja) | 2017-12-28 |
Family
ID=52669635
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530882A Pending JP2016538288A (ja) | 2013-11-15 | 2014-11-17 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| JP2019212877A Active JP6818851B2 (ja) | 2013-11-15 | 2019-11-26 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| JP2020218615A Pending JP2021073194A (ja) | 2013-11-15 | 2020-12-28 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019212877A Active JP6818851B2 (ja) | 2013-11-15 | 2019-11-26 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| JP2020218615A Pending JP2021073194A (ja) | 2013-11-15 | 2020-12-28 | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10017453B2 (ja) |
| EP (3) | EP3878835A1 (ja) |
| JP (3) | JP2016538288A (ja) |
| CN (2) | CN109232278A (ja) |
| ES (1) | ES2727387T3 (ja) |
| WO (1) | WO2015071766A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3129008A1 (en) * | 2015-12-18 | 2017-06-22 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| WO2022090482A1 (en) | 2020-10-30 | 2022-05-05 | Ds Biopharma Limited | Pharmaceutical compositions comprising 15-hetre and methods of use thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3055923A (en) * | 1960-03-25 | 1962-09-25 | Baxter Laboratories Inc | Fatty acid salts |
| IE47777B1 (en) | 1978-01-23 | 1984-06-13 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
| WO1990014824A1 (en) | 1988-01-14 | 1990-12-13 | Anders Frithz | Use of essential fatty acids for the preparation of a drug for the treatment of eczema |
| GB9111900D0 (en) | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| JPH05186342A (ja) | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| US5696166A (en) * | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| PL326750A1 (en) * | 1996-09-20 | 1998-10-26 | Atherogenics Inc | Method of diagnosing inflamatory diseases and mediators of such diseases |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| CA2332272A1 (en) * | 1998-05-15 | 1999-11-25 | University Of Vermont | Novel analogs of 16-hydroxyeicosatetraenoic acid |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| DE60021908T2 (de) * | 1999-11-09 | 2006-04-06 | Alcon Inc. | Hydroxyeicosatetraenoatsalze, zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges |
| CN100357244C (zh) | 2000-02-16 | 2007-12-26 | 布里格姆及妇女医院股份有限公司 | 阿司匹林触发的脂质介体 |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| DE10121252A1 (de) | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| WO2004072013A1 (ja) * | 2003-02-14 | 2004-08-26 | Taisho Pharmaceutical Co.,Ltd. | ヒドロキシエイコサジエン酸化合物 |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| US20070105954A1 (en) | 2003-12-31 | 2007-05-10 | Ingennus Limited | Formulation containing a carboxylic acid or an ester thereof |
| WO2005102309A2 (en) | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| EP1852114B1 (en) | 2005-02-14 | 2019-09-18 | Suntory Holdings Limited | Composition containing dihomo-y-linolenic acid (dgla) as active ingredient |
| TW200711649A (en) | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| WO2008021192A2 (en) | 2006-08-08 | 2008-02-21 | Lipomics Technologies, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| JP5101894B2 (ja) | 2007-01-15 | 2012-12-19 | サントリーホールディングス株式会社 | 高度不飽和脂肪酸及びこれを含有する脂質の製造方法 |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| WO2009154230A1 (ja) | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| GB0907601D0 (en) * | 2009-05-01 | 2009-06-10 | Equateq Ltd | Novel methods |
| US10154977B2 (en) | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US8936803B2 (en) | 2011-10-19 | 2015-01-20 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| JP2015500639A (ja) | 2011-11-29 | 2015-01-08 | ディグニティ サイエンシス リミテッド | ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法 |
| CN108524483A (zh) | 2012-01-06 | 2018-09-14 | 翁特拉制药公司 | 游离酸形式的ω-3多不饱和脂肪酸的富含dpa组合物 |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| ES2606392T3 (es) | 2012-04-04 | 2017-03-23 | Pronova Biopharma Norge As | Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas |
| US10568858B2 (en) | 2012-05-10 | 2020-02-25 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
| WO2014022816A2 (en) | 2012-08-03 | 2014-02-06 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| AU2015204531B2 (en) | 2014-01-10 | 2019-11-14 | Afimmune Limited | Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same |
| EP3151825B1 (en) | 2014-06-04 | 2020-03-25 | DS Biopharma Limited | Pharmaceutical compositions comprising dgla and use of same |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| CA3129008A1 (en) | 2015-12-18 | 2017-06-22 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| WO2017118911A1 (en) | 2016-01-07 | 2017-07-13 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and use of same |
-
2014
- 2014-11-17 ES ES14843234T patent/ES2727387T3/es active Active
- 2014-11-17 CN CN201811061377.2A patent/CN109232278A/zh active Pending
- 2014-11-17 EP EP21159762.0A patent/EP3878835A1/en not_active Withdrawn
- 2014-11-17 US US14/543,638 patent/US10017453B2/en active Active
- 2014-11-17 JP JP2016530882A patent/JP2016538288A/ja active Pending
- 2014-11-17 CN CN201480071412.2A patent/CN105899485B/zh not_active Expired - Fee Related
- 2014-11-17 EP EP19157319.5A patent/EP3546446A1/en not_active Withdrawn
- 2014-11-17 EP EP14843234.7A patent/EP3068757B1/en active Active
- 2014-11-17 WO PCT/IB2014/003027 patent/WO2015071766A1/en active Application Filing
-
2017
- 2017-12-01 US US15/828,700 patent/US10544088B2/en not_active Expired - Fee Related
-
2019
- 2019-11-26 JP JP2019212877A patent/JP6818851B2/ja active Active
- 2019-12-05 US US16/704,289 patent/US20200181064A1/en not_active Abandoned
-
2020
- 2020-12-28 JP JP2020218615A patent/JP2021073194A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2601127T3 (es) | Derivado de pirazol y su uso con fines médicos | |
| JP2015057451A5 (ja) | ||
| JP2014505733A5 (ja) | ||
| JP2014521735A5 (ja) | ||
| JP2017505285A5 (ja) | ||
| JP2013014622A5 (ja) | ||
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| JP2012255026A5 (ja) | ||
| JP2015038135A5 (ja) | ||
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2016511753A5 (ja) | ||
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| JP2017222722A5 (ja) | ||
| PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| JP2016510326A5 (ja) | ||
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| JP2015516419A5 (ja) | ||
| JP2015537009A5 (ja) | ||
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| JP2016515550A5 (ja) | ||
| JP2016538288A5 (ja) | ||
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| JP2016510332A5 (ja) | ||
| JP2014509637A5 (ja) |